Abstract
Glycogen synthase kinase 3 beta (GSK-3β) was one of the first kinases identified and studied, initially for its role in the regulation of glycogen synthesis. Over the past decade, interest in GSK-3β has grown far beyond glycogen metabolism, and this is due in large measure to the critical role that GSK-3β plays in the regulation of many other cellular processes, particularly cell proliferation and apoptosis. GSK-3β has been shown to regulate the proteolysis and sub-cellular compartmentalization of a number of proteins directly involved in the regulation of cell cycling, proliferation, differentiation and apoptosis. GSK-3β also regulates the degradation of proteins that regulate gene expression and thus affects a variety of important cell functions. Specifically, GSK-3β controls the degradation of β- catenin, the main effector of Wnt that regulates haematopoiesis and stem cell function. In this case GSK-3β is a negative regulator of Wnt. In contrast, GSK-3β positively regulates NF-κB, another important biochemical pathway also involved in the regulation of multiple aspects of normal and aberrant haematopoiesis. GSK-3β regulates degradation of IκB, a central inhibitor of NF-κB. In this way, GSK-3β acts to control the resistance of leukaemic cells to chemotherapy through the modulation of NF-κB, a critical factor in maintaining leukaemic cell growth. In addition, GSK-3β regulates the pro-inflammatory activity of NF-κB. As GSK-3β is a pleiotropic regulator, inhibitors may increase the range of novel anti-leukaemic and anti-inflammatory drugs that control immune response.
Keywords: Haematopoiesis, angiogenesis, leukaemogenesis, β-catenin, NF-κB, Wnt, haematopoietic stem cell, GSK-3β inhibition
Current Medicinal Chemistry
Title: The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Volume: 15 Issue: 15
Author(s): T. Holmes, T. A. O'Brien, R. Knight, R. Lindeman, G. Symonds and A. Dolnikov
Affiliation:
Keywords: Haematopoiesis, angiogenesis, leukaemogenesis, β-catenin, NF-κB, Wnt, haematopoietic stem cell, GSK-3β inhibition
Abstract: Glycogen synthase kinase 3 beta (GSK-3β) was one of the first kinases identified and studied, initially for its role in the regulation of glycogen synthesis. Over the past decade, interest in GSK-3β has grown far beyond glycogen metabolism, and this is due in large measure to the critical role that GSK-3β plays in the regulation of many other cellular processes, particularly cell proliferation and apoptosis. GSK-3β has been shown to regulate the proteolysis and sub-cellular compartmentalization of a number of proteins directly involved in the regulation of cell cycling, proliferation, differentiation and apoptosis. GSK-3β also regulates the degradation of proteins that regulate gene expression and thus affects a variety of important cell functions. Specifically, GSK-3β controls the degradation of β- catenin, the main effector of Wnt that regulates haematopoiesis and stem cell function. In this case GSK-3β is a negative regulator of Wnt. In contrast, GSK-3β positively regulates NF-κB, another important biochemical pathway also involved in the regulation of multiple aspects of normal and aberrant haematopoiesis. GSK-3β regulates degradation of IκB, a central inhibitor of NF-κB. In this way, GSK-3β acts to control the resistance of leukaemic cells to chemotherapy through the modulation of NF-κB, a critical factor in maintaining leukaemic cell growth. In addition, GSK-3β regulates the pro-inflammatory activity of NF-κB. As GSK-3β is a pleiotropic regulator, inhibitors may increase the range of novel anti-leukaemic and anti-inflammatory drugs that control immune response.
Export Options
About this article
Cite this article as:
Holmes T., O'Brien A. T., Knight R., Lindeman R., Symonds G. and Dolnikov A., The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia, Current Medicinal Chemistry 2008; 15 (15) . https://dx.doi.org/10.2174/092986708784638834
DOI https://dx.doi.org/10.2174/092986708784638834 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Using Microgravity for Defining Novel Anti-Atherosclerotic Therapy
Current Genomics Preclinical Studies of PROTACs in Hematological Malignancies
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation
Current Medicinal Chemistry miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Thymidylate Synthase Gene in Pharmacogenetics
Current Pharmacogenomics EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Drugs that Inhibit Tubulin Polymerization: The Particular Case of Podophyllotoxin and Analogues
Current Medicinal Chemistry - Anti-Cancer Agents Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients
Current Pharmacogenomics Dasatinib in the Treatment of Chronic Myeloid Leukemia
Current Signal Transduction Therapy Towards Liver-Directed Gene Therapy for Crigler-Najjar Syndrome
Current Gene Therapy Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Production of Retroviral Vectors: Review
Current Gene Therapy Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics DNA Mismatch Repair Deficiency, Resistance to Cancer Chemotherapy and the Development of Hypersensitive Agents
Current Topics in Medicinal Chemistry Cinnamic Acid Derivatives in Tuberculosis, Malaria and Cardiovascular Diseases - A Review
Current Organic Chemistry